305 related articles for article (PubMed ID: 31973138)
1. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Varytė G; Zakarevičienė J; Ramašauskaitė D; Laužikienė D; Arlauskienė A
Medicina (Kaunas); 2020 Jan; 56(2):. PubMed ID: 31973138
[TBL] [Abstract][Full Text] [Related]
2. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Ingwersen J; Aktas O; Hartung HP
Neurotherapeutics; 2016 Jan; 13(1):47-57. PubMed ID: 26701666
[TBL] [Abstract][Full Text] [Related]
3. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
5. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
6. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
7. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
8. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Salama S; Ahmed SF; Ibrahim Ismail I; Alroughani R
Clin Neurol Neurosurg; 2020 Oct; 197():106203. PubMed ID: 32919242
[No Abstract] [Full Text] [Related]
9. Update on disease-modifying treatments for multiple sclerosis.
Carrithers MD
Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis, a treatable disease .
Doshi A; Chataway J
Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
[TBL] [Abstract][Full Text] [Related]
11. Effector and regulatory B cells in Multiple Sclerosis.
Staun-Ram E; Miller A
Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
[TBL] [Abstract][Full Text] [Related]
12. Induction and escalation therapies in multiple sclerosis.
Fenu G; Lorefice L; Frau F; Coghe GC; Marrosu MG; Cocco E
Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):26-34. PubMed ID: 25938688
[TBL] [Abstract][Full Text] [Related]
13. Update on treatment in multiple sclerosis.
Callegari I; Derfuss T; Galli E
Presse Med; 2021 Jun; 50(2):104068. PubMed ID: 34033862
[TBL] [Abstract][Full Text] [Related]
14. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
15. Disease modifying therapies for relapsing multiple sclerosis.
Wingerchuk DM; Weinshenker BG
BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
[TBL] [Abstract][Full Text] [Related]
16. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 will change MS care forever - No.
Preziosa P; Rocca MA; Filippi M
Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
[No Abstract] [Full Text] [Related]
18. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
19. Preapproval and postapproval evidence on drugs for multiple sclerosis.
Gerardi C; Bertele' V; Rossi S; Garattini S; Banzi R
Neurology; 2018 May; 90(21):964-973. PubMed ID: 29695598
[TBL] [Abstract][Full Text] [Related]
20. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Rommer PS; Zettl UK
Expert Opin Pharmacother; 2018 Apr; 19(5):483-498. PubMed ID: 29528247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
